ARVINAS INC. - COMMON STOCK

Arvinas Announces Chief Financial Officer Transition

20 фев 2024 16:05:04 Источник Nasdaq GlobeNewswire

Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease

20 фев 2024 07:00:44 Источник Nasdaq GlobeNewswire

Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer

06 фев 2024 06:45:00 Источник Nasdaq GlobeNewswire

Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference

01 фев 2024 16:30:20 Источник Nasdaq GlobeNewswire

Arvinas Appoints Jared Freedberg as General Counsel

16 янв 2024 17:01:06 Источник Nasdaq GlobeNewswire

Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program

05 дек 2023 22:52:59 Источник Nasdaq GlobeNewswire

Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program

05 дек 2023 13:33:42 Источник Nasdaq GlobeNewswire

Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium

28 ноя 2023 17:05:13 Источник Nasdaq GlobeNewswire

Arvinas Announces Oversubscribed $350 Million Private Placement

27 ноя 2023 07:00:10 Источник Nasdaq GlobeNewswire

Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update

07 ноя 2023 07:00:34 Источник Nasdaq GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences

02 ноя 2023 07:00:59 Источник Nasdaq GlobeNewswire

Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC

22 окт 2023 07:00:58 Источник Nasdaq GlobeNewswire

Arvinas Gives Back to Local Greater New Haven Community in Second Annual Impact Day

18 окт 2023 07:00:27 Источник Nasdaq GlobeNewswire

Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023

15 окт 2023 18:07:41 Источник Nasdaq GlobeNewswire

Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023

15 окт 2023 18:05:45 Источник Nasdaq GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences

01 сен 2023 07:00:10 Источник Nasdaq GlobeNewswire

Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update

08 авг 2023 07:00:18 Источник Nasdaq GlobeNewswire

Arvinas and Pfizer Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant, an Investigational PROTAC® ER degrader being developed in ER+/HER2- Breast Cancer

31 июл 2023 16:30:14 Источник Nasdaq GlobeNewswire

Arvinas Announces Changes to its Board of Directors

15 июн 2023 16:30:26 Источник Nasdaq GlobeNewswire

Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H Mutations

08 июн 2023 07:00:41 Источник Nasdaq GlobeNewswire